Background: The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone continues to be proven to work in patients with relapsed or refractory multiple myeloma. The immunomodulatory agent pomalidomide plus dexamethasone continues to be proven to work in patients with multiple myeloma that’s refractory to lenalidomide along with a proteasome inhibitor.
Methods: Patients with multiple myeloma which was refractory or relapsed and refractory to lenalidomide along with a proteasome inhibitor were at random allotted to receive elotuzumab plus pomalidomide and dexamethasone (elotuzumab group) or pomalidomide and dexamethasone alone (control group). The main finish point was investigator-assessed progression-free survival.
Results: As many as 117 patients were at random allotted to the elotuzumab group (60 patients) or even the control group (57 patients). Following a minimum follow-up duration of 9.1 several weeks, the median progression-free survival was 10.3 several weeks within the elotuzumab group and 4.7 several weeks within the control group. The hazard ratio for disease progression or dying within the elotuzumab group compared to the control group was .54 (95% confidence interval [CI], .34 to .86 P=.008). The general response rate was 53% within the elotuzumab group compared to 26% within the control group (odds ratio, 3.25 95% CI, 1.49 to 7.11). The most typical grade three or four adverse occasions were neutropenia (13% within the elotuzumab group versus. 27% within the control group), anemia (10% versus. 20%), and hyperglycemia (8% versus. 7%). As many as 65% of the sufferers in every group had infections. Infusion reactions happened in 3 patients (5%) within the elotuzumab group.
Conclusions: Among patients with multiple myeloma in whom treatment with lenalidomide along with a proteasome inhibitor had unsuccessful, the chance of progression or dying was considerably lower among individuals who received elotuzumab plus pomalidomide and dexamethasone than among individuals who received pomalidomide plus dexamethasone alone.